Sir,

We read the findings by Adwani *et al*.\[[@ref1]\] with great interest. Differences in motor\[[@ref2]\] as well as nonmotor\[[@ref3]\] manifestations of Parkinson\'s disease (PD) have been observed in right-sided (R-PD) versus left-sided (L-PD) disease. However, some of these associations have been debated in the literature.

We recently recruited a number of PD patients (*n* = 31) as part of an ongoing neurocognitive study. The onset of PD was on the right in 16 patients and on the left in 15 patients. Both groups were of similar age (R-PD mean 65.5 years; L-PD mean 68.7 years) and male-to-female ratio (R-PD 75% males; L-PD 87% males). All patients were on dopamine replacement therapy.

Handedness was assessed by the Edinburgh handedness inventory.\[[@ref4]\] Except one patient who was ambidextrous, all patients were right handed. We assessed whether handedness-symptomatic side mismatch (i.e., left-sided symptom onset in a right-handed individual) who delay the interval between symptom onset and diagnosis. R-PD patients were diagnosed 2.1 (±1.0) years after symptoms onset, compared with 1.6 (±0.8) years in L-PD patients; this difference was not statistically significant (*P* = 0.15).

Mild cognitive impairment was equally distributed between R-PD (50%) and L-PD (53%) patients. Disease duration was similar between the two groups: 6.3 (±3.5) years for R-PD and 8.3 (±5.3) years for L-PD (*P* = 0.23). The extent of motor deficit was not different between the two groups as assessed by the Unified Parkinson\'s Disease Rating Scale (UPDRS-II) (14.7 vs. 17.3, *P* = 0.39, respectively) and the UPDRS-III (31.6 vs. 38.6, *P* = 0.13, respectively). The severity of symptoms of anxiety and depression (as assessed by the Hospital Anxiety and Depression Scale) was also similar between R-PD (mean 9.9 points) and L-PD (mean 9.7 points) patients (*P* = 0.95).

In conclusion, we found no difference in R-PD versus L-PD patients in relation to motor or psychological symptoms in our sample. Further insights may be obtained by comparing drug-naïve versus medicated PD patients as well as inclusion of PD patients with established PD-dementia.
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